Curative efficacy of granulocyte colony-stimulating factor in combination with entecavir in patients with hepatitis B virus related acute-on-chronic liver failure at early stage and its influences on levels of AngⅡ, TNF-α, and IL-10
TIAN Yuqiu ZHOU Ning JIANG Yongfang
Department of Infedtious Diseases, Xiangya No.2 Hospital of Central South University, Hu′nan Province, Changsha 410011, China
Abstract：Objective To investigate the curative efficacy of granulocyte colony-stimulating factor in combination with entecavir in patients with hepatitis B virus related acute-on-chronic liver failure (ACLF) at early stage and its influences on levels of angiotensin Ⅱ (AngⅡ), tumor necrosis factor α (TNF-α), interleukin 10 (IL-10). Methods From January 2016 to June 2017, in Department of Infedtious Diseases, Xiangya No.2 Hospital of Central South University, 84 patients with hepatitis B virus related ACLF at early stage were collected, according to random number table, they were divided into the control group and the observation group, with 42 cases in each group. Besides conventional treatments, the control group was treated with entecavir, while the observation group was treated with granulocyte colony-stimulating factor in combination with entecavir. Curative efficacy, levels of indices of liver function, AngⅡ, TNF-α and IL-10 were compared between the two groups. Results The total therapeutic efficacy ratio in the observation group was statistically higher than that in the control group, the difference was statistically significant (P < 0.05). Compared with the control group, the observation group had lower level of total bilirubin and higher levels of albumin, prothrombin activity after treatment, the differences were statistically significant (P < 0.05). After treatment, compared with the control group, the observation group had lower levels of AngⅡ, TNF-α and higher level of IL-10, the differences were statistically significant (P < 0.05). Conclusion Granulocyte colony-stimulating factor in combination with Entecavir has well application effect in patients with hepatitis B virus related ACLF at early stage with a high therapeutic efficacy ratio. And it can effectively improve liver function, reduce level of AngⅡ and improve inflammatory reaction.
田玉球 周宁 蒋永芳. 粒细胞集落刺激因子联合恩替卡韦治疗早期乙肝慢加急性肝衰竭的效果及对AngⅡ、TNF-α和IL-10的影响[J]. 中国医药导报, 2018, 15(17): 139-142.
TIAN Yuqiu ZHOU Ning JIANG Yongfang . Curative efficacy of granulocyte colony-stimulating factor in combination with entecavir in patients with hepatitis B virus related acute-on-chronic liver failure at early stage and its influences on levels of AngⅡ, TNF-α, and IL-10. 中国医药导报, 2018, 15(17): 139-142.
[1] 吴蓓，朱丽，段萌，等. 双重血浆分子吸附系统治疗乙肝慢加急肝衰竭患者疗效及其对T淋巴细胞亚型的影响[J].疑难病杂志，2016，15（6）：584-587.
[2] 李晓鸥，朱元东，刘宏景，等.血管活性物质分布及其在肝肾综合征发病中的作用[J].医学研究杂志，2006，35（4）：41-43.
[3] 唐娟，邓薇，唐静，等.双重血浆分子吸附系统对慢加急肝衰竭患者血清炎性因子、肝功能及免疫功能的影响[J].疑难病杂志，2017，16（9）：903-906.
[4] Fattovich G. Entecavir versus Lamivudine for patients with hbeag-negative chronic hepatitis B [J]. N Eng J Med，2006， 354（10）：1011.
[5] 许祥，刘晓燕，陈婧，等.粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究[J].传染病信息，2016，29（5）：279-283.
[6] 王宇明，张南.从慢加急性肝衰竭共识讨论到肝衰竭定义和分型诊断[J].中华肝脏病杂志，2008，16（6）：404-407.
[7] 中华医学会感染病学分会肝功能衰竭与人工肝学组. 肝功能衰竭诊治指南（2012年版)[J].中华传染病杂志，2013，31（3）：129-137.
[8] 朱其荣，李玲，梅小平.恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭的近期疗效[J].广东医学，2016， 37（8）：1218-1220.
[9] 曹竹君，谢青.慢加急性肝衰竭患者的感染问题:发生、特征及其对疾病进展和预后的影响[J].中华肝脏病杂志，2018，21（1）：6-9.
[10] 苗静，吴素琼，郭丽颖，等.甲胎蛋白和胆碱酯酶在乙型肝炎病毒相关 慢加急性肝衰竭患者中应用价值的研究[J].中华危重病急救医学，2016，28（3）：257-261.
[11] 刘菲菲，吴吉圆，张海月，等.慢加急性乙型肝炎肝衰竭临床特征及血浆置换治疗对其预后的影响[J].实用肝脏病杂志，2016，19（2）：188-191.
[12] Jeon HJ，Jung SW，Park NH，et al. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir [J]. Clin Mol Hepatol，2017，23（3）：230-238.
[13] 唐瑞梅，林丽娥，朱永，等.重组粒细胞集落刺激因子对再生障碍性贫血并感染患者免疫功能的影响[J].中国医药导报，2016，13（26）：60-63.
[14] 胡宗晶，韩明子，金世柱，等.粒细胞集落刺激因子动员骨髓干细胞治疗肝脏疾病的研究[J].肠病学和肝病学杂志，2011，20（1）：21-24.
[15] Sarin SK，Kedarisetty CK，Abbas Z，et al. Acute-on-chronic liver failure：consensus recommendations of the Asian Pacific Association for the Study of the Liver（APASL)[J]. Hepatol Int，2014，8（4）：453-471.
[16] 陈艳芳，张永标，梁彩倩.慢加急性肝衰竭并发肝肾综合征的预测因素分析[J].临床肝胆病杂志，2015，31（9）：1422-1425.
[17] 顾锡炳，徐月琴.医用三氧治疗系统对肝衰竭患者肾素血管紧张素Ⅱ和醛固酮的影响[J].实用肝脏病杂志，2009， 12（4）：289-291.
[18] 田辉，孙颖，滕光菊，等.慢加急性乙型肝炎肝衰竭患者肝组织IFN-γ、TNF-α和IL-10的表达[J].实用肝脏病杂志，2011，14（2）：116-118.
[19] 炉军，何金秋.慢加急性肝衰竭患者IL-6、IL-10、TNF-α水平变化与肝性脑病的关系[J].实用临床医学，2016， 17（10）：16-18.
[20] 施文娟，成军.HBV相关慢加急性肝功能衰竭患者血清IL-4和IL-10的表达及临床意义[J].中华实验和临床感染病杂志：电子版，2013，7（2）：75-78.
[21] 韩英，崔丽娜，郭冠亚.慢加急性肝衰竭的免疫治疗[J].临床肝胆病杂志，2017，33（9）：1677-1682
2018, Vol. 15 
京公网安备 11010502046598号